肺がんワクチンの世界市場・パイプライン見通し

KuicK Researchが発行した調査報告書(KUIK70405)
◆英語タイトル:Global Lung Cancer Vaccine Market & Pipeline Outlook 2022
◆商品コード:KUIK70405
◆発行会社(リサーチ会社):KuicK Research
◆発行日:2016年12月
◆ページ数:150
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single userUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Multi UserUSD3,600 ⇒換算¥406,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuicK Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。KuicK Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

“Global Lung Cancer Vaccine Market & Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the global lung cancer vaccine market. Currently there are 3 lung cancer vaccines commercially available in the market. This report analyzes the ongoing clinical trial of 30 lung cancer vaccines in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the lung cancer vaccines. Currently there are 9 lung cancer vaccines in advance Phase-II clinical trials followed by 8 vaccines Phase-I/II trials.
Lung cancer is emerging as one of the most lethal malignancy having high morbidity and mortality rates across the world. High mortality rates, high unmet medical necessities and modest efficacy of presently available lung cancer therapeutics have encouraged the demand for better and efficient lung cancer vaccines. More funds are being diverted into research and development segment to come up with lung cancer vaccine having high safety and efficacy profiles. Pharmaceutical companies have recognized the marketing potential of these vaccines in generating significant revenues and providing efficient medical care to patients across the world. Lung cancer vaccine market is largely untapped and offers significant opportunities to pharmaceutical companies to occupy large market shares across the globe.

At present majority of the lung cancer vaccines are in experimental stage and are still stuck in clinical trials due to which large unmet medical demands are still to be fulfilled. Boehringer Ingelheim and CureVac are developing lung cancer vaccine called CV9202 for the treatment of lung cancer which is at higher phase of clinical trials. GlaxoSmithKline is developing MAGE-A3 lung cancer vaccine which is also under investigation for other malignancies. Cell Genesys pharmaceutical company is developing GVAX for lung cancer and many clinical end points have been achieved during investigation.

Early market introduction of these drugs will be the major factor responsible for the increased marketing potential. Over time, they are expected to generate significant revenues owing to their safety and efficacy levels but till then this gap will be filled by other therapeutics. Further, those lung cancer vaccines which will make late entry have to face competition with previously marketed lung cancer vaccines giving them severe competition. This shows that pharmaceutical companies have to introduce their products in market as soon as possible to occupy major market shares across the globe. Thus, impact of early entrant will be more in global market and help them to generate significant revenues for some time before entry of worthy competitors.

Many pharmaceutical companies have already introduces cancer vaccines in global market and lung cancer segment is expected to get its first contender in coming years. Addition of lung cancer vaccines in this segment will further increase the size of global cancer vaccine market. Several other products belonging to different cancer indication will be entering in the global market leading to further increase in the market size. Advent of lung cancer vaccines is expected to improve this situation by increasing present survival rates and improve quality of life. Introduction of lung cancer vaccines are expected to gain major market shares among other cancer vaccines due to large patient population as compared to other disease indication.

【レポートの目次】

1. What are Cancer Vaccines?

2. Mechanism of Cancer Vaccines
2.1 Idiotype Cancer Vaccine Mechanism
2.2 Cellular Cancer Vaccines Mechanism
2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. Overview of Lung Cancer Proliferation
3.1 Lung Cancer Invasion
3.1.1 Transformation of Normal Cell into Cancerous Cell
3.1.2 Tumor Heterogeneity & Cancer Stem Cells
3.1.3 Dissemination of Tumor Cell & Cell Motility
3.2 Lung Cancer Metastasis
3.2.1 Angiogenesis & Lymphangiogenesis
3.2.2 Intravasation, Circulation & Extravasation

4. Lung Cancer Vaccine Mechanism
4.1 Mechanism of Lung Cancer Vaccination
4.2 Rationale for Using Lung Cancer Vaccines
4.2.1 Regulatory T- Lymphocytes (Tregs)
4.2.2 Macrophages

5. Clinical Trials of Lung Cancer Vaccines

6. Global Lung Cancer Incidence Rate
6.1 U.S
6.2 Europe
6.3 Asia
6.4 Rest of the World

7. Global Lung Cancer Vaccine Market Overview
7.1 Current Market Scenario
7.2 Global Lung Cancer Vaccine Pipeline Overview
7.3 Global Lung Cancer Vaccine Market Future Prospects

8. Need for Personalized Breast Cancer Vaccines

9. Lung Cancer Vaccine Clinical Pipeline by Company & Phase
9.1 Preclinical
9.2 Phase-I
9.3 Phase-II

10. Non Small Cell Lung Cancer Vaccine Clinical Pipeline by Company & Phase
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-II/III
10.7 Phase-III

11. Small cell lung Cancer Vaccine Clinical Pipeline by Company & Phase
11.1 Phase-II

12. Marketed Lung Cancer Vaccine Clinical & Patent Insight
12.1 Epidermal Growth Factor Cancer Vaccine
12.2 Mycidac-C™
12.3 Racotumomab (Vaxira)

13. No Development Reported & Discontinued Lung Cancer Vaccine Clinical Pipeline by Company, Indication & Phase
13.1 No Development Reported
13.2 Discontinued
13.3 Suspended

14. Competitive Landscape
14.1 Argos Therapeutics
14.2 Boehringer Ingelheim
14.3 Cadila Pharmaceuticals
14.4 CureVac
14.5 Eli Lily
14.6 Galaxo
14.7 ImClone Systems
14.8 Inovio Pharmaceuticals
14.9 Merck
14.10 NewLink Genetics
14.11 Northwest Biotherapeutics
14.12 Ono Pharmaceutical
14.13 Oncothyreon Incorporation
14.14 OSE Immunotherapeutics

Figure 1-1: Categorization & Function of Cancer Vaccines
Figure 2-1: Classification of Different Types of Cancer vaccines
Figure 3-1: Major Steps Involved in Cancer Invasiveness
Figure 4-1: Mechanism of Lung Cancer Vaccination
Figure 6-1: US – Lung Cancer New Incidence & Deaths, 2016
Figure 6-2: US – Lung Cancer New Incidence by Gender, 2016
Figure 6-3: US – Lung Cancer Deaths by Gender, 2016
Figure 6-4: Japan – Lung Cancer New Incidence & Deaths, 2016
Figure 6-5: Japan – Lung Cancer New Incidence by Gender, 2016
Figure 6-6: Japan – Lung Cancer Deaths by Gender, 2016
Figure 6-7: China – Lung Cancer Patients, 2016 & 2022
Figure 6-8: India – Lung Cancer New Incidence, 2016 & 2022
Figure 6-9: Canada – Lung Cancer Deaths by Gender, 2016
Figure 7-1: Global Lung Cancer Vaccine Clinical Pipeline by Phase (%), 2016 till 2022
Figure 7-2: Global Lung Cancer Vaccine Clinical Pipeline by Phase (Numbers), 2016 till 2022
Figure 7-3: Global Non-small cell lung cancer Vaccine Clinical Pipeline by Phase (%), 2016 till 2022
Figure 7-4: Global Non-small cell lung cancer Vaccine Clinical Pipeline by Phase (Number), 2016 till 2022
Figure 7-5: Global Lung Cancer Vaccine Clinical Pipeline by Phase (%), 2016 till 2022
Figure 7-6: Global Lung Cancer Vaccine Clinical Pipeline by Phase (Numbers), 2016 till 2022
Figure 8-1: Overview of Personalized Cancer Vaccines Development
Figure 8-2: Methodology for the Development of Personalized Cancer Vaccine
Figure 8-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine
Figure 14-1: Inovio Pharmaceuticals Clinical Pipeline
Figure 14-2: NewLink Genetics Corporation Clinical Pipeline
Figure 14-3: Northwest Biotherapeutics Clinical Pipeline


【レポートのキーワード】

肺がんワクチン

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 肺がんワクチンの世界市場・パイプライン見通し(Global Lung Cancer Vaccine Market & Pipeline Outlook 2022)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆